EGFR Expression

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chordoma1
EGFR Expression	Lapatinib	Predictive	B	Supports Sensitivity Response	2	accepted	EID1984 18 advanced progressing chordoma patients that were positive for EGFR by at least one technique (immunohistochemistry and/or phospho-arrays, real-time polymerase chain reaction for EGFR ligands, FISH)… (full text at CIViC) PMID 23559153 · Stacchiotti et al., 2013 · Open in CIViC	civic
Glioblastoma1
EGFR Expression	3-Dimensional Conformal Radiation Therapy + Nimotuzumab + TemozolomideCombination	Predictive	B	Supports Sensitivity Response	2	submitted	EID8299 A single-arm phase 2 trial evaluated the benefit of adding nimotuzumab to standard chemo-radiation treatment for GBM. 36 patients were evaluable for efficacy, all of whom had EGFR positive tumours by …

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Chordoma1

EGFR Expression

Lapatinib

Predictive

Supports Sensitivity Response

accepted

EID1984

18 advanced progressing chordoma patients that were positive for EGFR by at least one technique (immunohistochemistry and/or phospho-arrays, real-time polymerase chain reaction for EGFR ligands, FISH)… (full text at CIViC)

PMID 23559153 · Stacchiotti et al., 2013 · Open in CIViC

civic

Glioblastoma1

EGFR Expression

3-Dimensional Conformal Radiation Therapy + Nimotuzumab + TemozolomideCombination

Predictive

Supports Sensitivity Response

submitted

EID8299

A single-arm phase 2 trial evaluated the benefit of adding nimotuzumab to standard chemo-radiation treatment for GBM. 36 patients were evaluable for efficacy, all of whom had EGFR positive tumours by …

Lung Adenocarcinoma1
EGFR Expression	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4213 A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC) PMID 21969500 · Brugger et al., 2011 · Open in CIViC	civic

Lung Adenocarcinoma1

EGFR Expression

Erlotinib

Predictive

Supports Sensitivity Response

—

submitted

EID4213

A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC)

PMID 21969500 · Brugger et al., 2011 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma1
EGFR Expression	Gefitinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID4877 Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of … (full text at CIViC) PMID 12748244 · Fukuoka et al., 2003 · Open in CIViC	civic

Lung Non-Small Cell Carcinoma1

EGFR Expression

Gefitinib

Predictive

Supports Sensitivity Response

accepted

EID4877

Double blind Phase II clinical trial evaluated 208 patients for efficacy of gefitinib against non-small cell lung cancer. For individuals taking 250mg/day, they observed an objective response rate of … (full text at CIViC)

PMID 12748244 · Fukuoka et al., 2003 · Open in CIViC

civic

Malignant Breast Neoplasm1
EGFR Expression	(prognostic)	Prognostic	D	Supports Poor Outcome	4	submitted	EID7445 91 cases of breast cancer were divided into two groups: pre and post-menopausal, with 47 in the first and 44 in the latter. The relationship between KI-67, a marker for increased proliferation, in com… (full text at CIViC) PMID 2372767 · Toi et al., 1990 · Open in CIViC	civic

Malignant Breast Neoplasm1

EGFR Expression

(prognostic)

Prognostic

Supports Poor Outcome

submitted

EID7445

91 cases of breast cancer were divided into two groups: pre and post-menopausal, with 47 in the first and 44 in the latter. The relationship between KI-67, a marker for increased proliferation, in com… (full text at CIViC)

PMID 2372767 · Toi et al., 1990 · Open in CIViC

civic

Malignant Colorectal Neoplasm3
EGFR Expression	Cetuximab	Predictive	B	Supports Sensitivity Response	4	accepted	EID1572 Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285).… (full text at CIViC) PMID 18003960 · Jonker et al., 2007 · Open in CIViC	civic
EGFR Expression	Cetuximab	Predictive	B	Supports Sensitivity Response	1	accepted	EID1709 57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a parti… (full text at CIViC) PMID 14993230 · Saltz et al., 2004 · Open in CIViC	civic
EGFR Expression	Panitumumab	Predictive	B	Supports Sensitivity Response	2	accepted	EID1708 463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or B… (full text at CIViC) PMID 17470858 · Van Cutsem et al., 2007 · Open in CIViC	civic

Malignant Colorectal Neoplasm3

EGFR Expression

Cetuximab

Predictive

Supports Sensitivity Response

accepted

EID1572

Patients with refractory colorectal cancer expressing immunohistochemically detectable EGFR were randomly assigned to receive treatment with cetuximab (n=287) or receive supportive care alone (n=285).… (full text at CIViC)

PMID 18003960 · Jonker et al., 2007 · Open in CIViC

civic

EGFR Expression

Cetuximab

Predictive

Supports Sensitivity Response

accepted

EID1709

57 patients with chemorefractory colorectal cancer expressing EGFR (IHC staining) were treated with single-agent cetuximab in this phase 2 study. Five patients (9%; 95% CI, 3% to 19%) achieved a parti… (full text at CIViC)

PMID 14993230 · Saltz et al., 2004 · Open in CIViC

civic

EGFR Expression

Panitumumab

Predictive

Supports Sensitivity Response

accepted

EID1708

463 patients with 1% or more EGFR tumor cell membrane staining, with metastatic CRC progressive after standard chemotherapy were randomized to panitumumab plus best supportive care (BSC, n = 231) or B… (full text at CIViC)

PMID 17470858 · Van Cutsem et al., 2007 · Open in CIViC

civic

Evidence by cancer (8 items)

Clinical significance (0)